My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
April 2012
Top Stories
IDSA Continues Push for Antibiotic Incentives, Members Can Help

Legislation to stimulate antibiotic development is heating up on Capitol Hill, and IDSA members can help during this critical time by contacting their members of Congress. IDSA continues to strongly advocate for the creation of a new antibiotic approval pathway to spur new antibiotic research and development (R&D) as part of the Food and Drug Administration Prescription Drug User Fee Act (PDUFA) reauthorization legislation.

The Society’s proposed Limited Population Antibacterial Drug (LPAD) pathway would provide an important new approval option for companies interested in developing drugs for serious resistant infections with few or no existing treatment options. Fourteen drug companies and 23 health and medical groups have come out in support of the proposal (see IDSA press release).

IDSA also recommends that PDUFA:

  • designate a lead federal agency to explore opportunities for public private collaborations to spur antibiotic R&D
  • direct the National Institute of Allergy and Infectious Disease to explore the feasibility of establishing a clinical specimen repository to ease diagnostics R&D

View the latest Antibiotic Resistance Policy Newsletter to see what IDSA is saying to members of Congress on this critical issue, and take action today.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
Rhinosinusitis Guideline Podcast Now Online
New Guideline Pocketcard: Treating CAP in Children
MRSA Guidelines Slide Set Available
Fever and Neutropenia Guideline Now in Japanese
Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
IDSA, Physician Groups Urge CMS to Re-Evaluate Penalty Timelines
Global ID
WHO Issues New Guidance to Prevent HIV in Discordant Couples, Infants
NIH Launches Initiative to Mentor Young Global Health Researchers
Interview Series: CDCís Role in Global HIV and TB
Policy and Advocacy
FDA Announces Voluntary Plan to Limit Antibiotic Use on the Farm
Your Colleagues
CDCís Antimicrobial Resistance Working Group Announces New Members
Education & Resources
IDSA, HIVMA Can Help with ABIM Recertification
CDC Webcast: Multidrug-Resistant Gonorrhea and Public Health
Top Stories
From the President:
Supporting the Next Generation of Our Field
IDSA Continues Push for Antibiotic Incentives, Members Can Help
EIN Update: Vancomycin and Acute Renal Toxicity
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.